For example, poly ADP-ribose polymerase 1 (PARP1) is involved in multiple DNA repair pathways to maintain genomic stability so PARP1 inhibitors have been approved to treat ovarian cancer, breast cancer, and other DNA repair-deficient tumors (Ray Chaudhuri & Nussenzweig, 2017). Here, PARP1 is linked to breast carcinoma.